PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 77 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.36 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $114,625,000 | -38.7% | 5,827,415 | 0.0% | 8.82% | -41.0% |
| Q3 2021 | $187,060,000 | -5.2% | 5,827,415 | 0.0% | 14.97% | -17.7% |
| Q2 2021 | $197,258,000 | -9.9% | 5,827,415 | 0.0% | 18.19% | +3.6% |
| Q1 2021 | $218,878,000 | +13.1% | 5,827,415 | 0.0% | 17.56% | +17.8% |
| Q4 2020 | $193,587,000 | -9.4% | 5,827,415 | 0.0% | 14.91% | -22.3% |
| Q3 2020 | $213,691,000 | +11.4% | 5,827,415 | 0.0% | 19.18% | +13.9% |
| Q2 2020 | $191,780,000 | +2.0% | 5,827,415 | -20.0% | 16.84% | -21.0% |
| Q1 2020 | $188,080,000 | -17.1% | 7,284,269 | 0.0% | 21.32% | -43.9% |
| Q4 2019 | $226,832,000 | – | 7,284,269 | – | 38.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
| Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
| Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
| Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
| 683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
| Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
| Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
| StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
| MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
| Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |